Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer-Reference-Cited by-同舟云学术

Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer

Published:2019-05-17 Issue:5 Volume:2 Page:e194154
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Boyne Devon J.¹²,Cuthbert Colleen A.³,O’Sullivan Dylan E.⁴,Sajobi Tolulope T.¹,Hilsden Robert J.⁵,Friedenreich Christine M.¹²³,Cheung Winson Y.³⁵,Brenner Darren R.¹²³

Affiliation:

1. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

2. Department of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Calgary, Alberta, Canada

3. Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

4. Department of Public Health Sciences, School of Medicine, Queen’s University, Kingston, Ontario, Canada

5. Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

http:///jamanetworkopen/article-pdf/2/5/e194154/17572244/boyne_2019_oi_190181.pdf

Reference57 articles.

1. Duration of adjuvant chemotherapy for stage III colon cancer.;Grothey;N Engl J Med,2018

2. NCCN guidelines insights: colon cancer, version 2.2018.;Benson;J Natl Compr Canc Netw,2018

3. Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer.;Des Guetz;Cochrane Database Syst Rev,2010

4. Adjuvant chemotherapy for high-risk stage II and stage III colon cancer: timing of initiation and optimal duration.;Cruz;J BUON,2018

5. Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement.;Moher;BMJ,2009

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis;International Journal of Surgery;2024-02-13

2. Trends and Prescriber Variation in the Duration of Oxaliplatin-Containing Adjuvant Chemotherapy for Stage III Colon Cancer From 2007 to 2019: A Population-Based Retrospective Cohort Study;Clinical Colorectal Cancer;2023-12

3. The Association of Oxaliplatin-Containing Adjuvant Chemotherapy Duration with Overall and Cancer-Specific Mortality in Individuals with Stage III Colon Cancer: A Population-Based Retrospective Cohort Study;Current Oncology;2023-07-06

4. Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role?;Clinical Colorectal Cancer;2023-06

5. Comparison of Postoperative Outcome and Prognosis Among Laparoscopic Left Colectomy and Laparoscopic Sigmoidectomy in Sigmoid Colon Cancer Patients: A Propensity Score Matching Study;Cancer Control;2023-04